已收盤 02-06 16:00:00 美东时间
-0.350
-1.28%
Evertec ( ($EVTC) ) has issued an update. On February 2, 2026, Evertec announce...
02-03 05:53
BRIEF-Evertec To Acquire Dimensa For R$950 Million Feb 2 (Reuters) - Evertec Inc EVTC.N : EVERTEC TO ACQUIRE DIMENSA FOR R$950 MILLION Source text: ID:nBwknrLGa Further company coverage: EVTC.N (( Reuters.Briefs@thomsonreuters.com ;))
02-03 05:35
EVERTEC, Inc. (NYSE:EVTC) ("Evertec", the "Company", "we" or "our") today announced it has entered into a definitive agreement to acquire Dimensa, S.A. ("Dimensa"), a B2B technology provider serving financial
02-03 05:32
Fintech Evertec to buy B3-Totvs joint venture Dimensa for $181 million SAO PAULO, Feb 2 (Reuters) - Latin American fintech Evertec EVTC.N on Monday said it will acquire Dimensa, a joint venture formed by Brazilian software firm Totvs TOTS3.SA and the country's stock exchange operator B3 B3SA3.SA , f
02-03 05:30
Evertec Acquires Brazil’s Dimensa for R$950 Million Evertec Inc. has entered into a definitive agreement to acquire Dimensa, S.A., a B2B technology provider serving financial institutions in Brazil, for R$950 million (approximately USD $181 million). The deal will expand Evertec's Funds product offe
02-03 05:27
Evertec übernimmt Dimensa für 950 Millionen Reais Evertec Inc. übernimmt den brasilianischen B2B-Technologieanbieter Dimensa S.A. für einen Kaufpreis von 950 Millionen brasilianischen Real (etwa 181 Millionen US-Dollar). Mit der Übernahme stärkt Evertec sein Angebot im Bereich Fonds und erweitert se
02-03 05:27
Evertec Mexico Chief Pledges to Drive Digital Payment Growth Juan Rial, the new Commercial Head of Evertec in Mexico, outlined his vision for accelerating the digitalization of payments in the country during a recent interview. He emphasized that despite progress, many Mexicans remain outside formal
01-27 05:09
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从12美元升至15美元;Canaccord Genuity:维持Viking Therapeutics"买入"评级,目标价从106美元升至107美元
2025-11-13 09:58
今日重点评级关注:Guggenheim:维持InflaRx"买入"评级,目标价从10美元升至22美元;巴克莱:维持Tandem糖尿病护理"超配"评级,目标价从51美元升至55美元
2025-11-11 10:49
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 17:17